Literature DB >> 2881976

Characterization of binding of 3H-SCH 23390 to dopamine D-1 receptors. Correlation to other D-1 and D-2 measures and effect of selective lesions.

J Hyttel, J Arnt.   

Abstract

The binding of 3H-SCH 23390 to membranes from rat and mouse brain tissue has been investigated. The binding was saturable and reached equilibrium after 60 minutes. Nonspecific binding was low. Association and dissociation rates were Mg++-sensitive. In almost all respects the binding of 3H-SCH 23390 was comparable to the binding of 3H-piflutixol and 3H-cis(Z)-flupentixol. The density of binding sites in striatum was greater than in limbic structures which in turn was greater than in frontal cortex. The density of binding sites in these structures were comparable with those of 3H-piflutixol and 3H-cis(Z)-flupenthixol, 2-3 times higher than the D-2-receptor density. Whereas an increase was seen in 3H-SCH 23390 binding. The binding was decreased approximately 72% 3 weeks after unilateral kainic acid lesion whereas that of 3H-spiperone was only decreased 56%. Finally, the affinities of neuroleptics to the 3H-SCH 23390-binding sites correlated to the affinities to 3H-piflutixol-binding sites and to the effects on DA-sensitive adenylate cyclase. Agonist competition curves were shallow and the data best fit a two-site model composed of a high and a low affinity component. Thus, 3H-SCH 23390 is regarded as a highly selective ligand for brain dopamine D-1 receptors in vitro.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2881976     DOI: 10.1007/bf02098496

Source DB:  PubMed          Journal:  J Neural Transm            Impact factor:   3.575


  26 in total

1.  Dopamine-sensitive adenylate cyclase in caudate nucleus of rat brain, and its similarity to the "dopamine receptor".

Authors:  J W Kebabian; G L Petzold; P Greengard
Journal:  Proc Natl Acad Sci U S A       Date:  1972-08       Impact factor: 11.205

2.  Conversion of dopamine D1 receptors from high to low affinity for dopamine.

Authors:  P Seeman; C Ulpian; D Grigoriadis; I Pri-Bar; O Buchman
Journal:  Biochem Pharmacol       Date:  1985-01-01       Impact factor: 5.858

3.  SCH 23390 - the first selective dopamine D-1 antagonist.

Authors:  J Hyttel
Journal:  Eur J Pharmacol       Date:  1983-07-15       Impact factor: 4.432

4.  How to analyze binding, enzyme and uptake data: the simplest case, a single phase.

Authors:  J A Zivin; D R Waud
Journal:  Life Sci       Date:  1982-04-26       Impact factor: 5.037

5.  Inhibition of [3H]dopamine accumulation in rat striatal synaptosomes by psychotropic drugs.

Authors:  J Hyttel
Journal:  Biochem Pharmacol       Date:  1978-04-01       Impact factor: 5.858

6.  Biochemical effects and drug levels in rats after long-term treatment with the specific 5-HT-uptake inhibitor, citalopram.

Authors:  J Hyttel; K F Overø; J Arnt
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

7.  Characteristics of 3H-cis-flupenthixol binding to calf brain membranes.

Authors:  A J Cross; F Owen
Journal:  Eur J Pharmacol       Date:  1980-08-08       Impact factor: 4.432

8.  SCH 23390, a potential benzazepine antipsychotic with unique interactions on dopaminergic systems.

Authors:  L C Iorio; A Barnett; F H Leitz; V P Houser; C A Korduba
Journal:  J Pharmacol Exp Ther       Date:  1983-08       Impact factor: 4.030

9.  Hyperactivity induced by stimulation of separate dopamine D-1 and D-2 receptors in rats with bilateral 6-OHDA lesions.

Authors:  J Arnt
Journal:  Life Sci       Date:  1985-08-26       Impact factor: 5.037

10.  Assay of dopamine receptors with [alpha-3H]flupenthixol.

Authors:  R M Huff; P B Molinoff
Journal:  J Pharmacol Exp Ther       Date:  1985-01       Impact factor: 4.030

View more
  13 in total

1.  Neuroanatomical substrates mediating the aversive effects of D-1 dopamine receptor antagonists.

Authors:  T S Shippenberg; R Bals-Kubik; A Huber; A Herz
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

2.  SKF-83566, a D1-dopamine receptor antagonist, inhibits the dopamine transporter.

Authors:  Melissa A Stouffer; Solav Ali; Maarten E A Reith; Jyoti C Patel; Federica Sarti; Kenneth D Carr; Margaret E Rice
Journal:  J Neurochem       Date:  2011-07-21       Impact factor: 5.372

3.  Effects of the partial dopamine receptor agonists SDZ 208-911, SDZ 208-912 and terguride on central monoamine receptors. A behavioral, biochemical and electrophysiological study.

Authors:  K Svensson; A Ekman; M F Piercey; W E Hoffmann; J T Lum; A Carlsson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-09       Impact factor: 3.000

4.  Effect of clozapine upon schedule-induced polydipsia (SIP) resembles neither the actions of dopamine D1 nor D2 blockade.

Authors:  M Didriksen; G M Olsen; A V Christensen
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

5.  Sex differences and the role of dopamine receptors in the reward-enhancing effects of nicotine and bupropion.

Authors:  Scott T Barrett; Trevor N Geary; Amy N Steiner; Rick A Bevins
Journal:  Psychopharmacology (Berl)       Date:  2016-10-01       Impact factor: 4.530

6.  D1 receptor binding in rat striatum: modification by various D1 and D2 antagonists, but not by sibutramine hydrochloride, antidepressants or treatments which enhance central dopaminergic function.

Authors:  S C Cheetham; C J Kettle; K F Martin; D J Heal
Journal:  J Neural Transm Gen Sect       Date:  1995

7.  Antiemetic prophylaxis with promethazine or droperidol in paediatric outpatient strabismus surgery.

Authors:  V F Blanc; P Ruest; J Milot; J L Jacob; A Tang
Journal:  Can J Anaesth       Date:  1991-01       Impact factor: 5.063

8.  Neonatal dopamine lesion in the rat results in enhanced adenylate cyclase activity without altering dopamine receptor binding or dopamine- and adenosine 3':5'-monophosphate-regulated phosphoprotein (DARPP-32) immunoreactivity.

Authors:  J Luthman; E Lindqvist; D Young; R Cowburn
Journal:  Exp Brain Res       Date:  1990       Impact factor: 1.972

9.  Molecular structure and dynamics of cis(Z)-and trans(E)-flupenthixol and clopenthixol.

Authors:  I Sylte; S G Dahl
Journal:  Pharm Res       Date:  1991-04       Impact factor: 4.200

10.  A receptor-based model for dopamine-induced fMRI signal.

Authors:  Joseph B Mandeville; Christin Y M Sander; Bruce G Jenkins; Jacob M Hooker; Ciprian Catana; Wim Vanduffel; Nathaniel M Alpert; Bruce R Rosen; Marc D Normandin
Journal:  Neuroimage       Date:  2013-03-01       Impact factor: 6.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.